Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
Leukemic cell growth was significantly reduced when treated with MT-401 OTS.
- Leukemic cell growth was significantly reduced when treated with MT-401 OTS.
- Marker has established a cellular inventory of 8 lines manufactured from healthy donors, with ongoing efforts to further expand the inventory.
- Marker anticipates that the first patient will be treated with MT-401 OTS during the first half of 2024.
- If MT-401 OTS is successful in clinical trials, we will consider expanding the OTS multiTAA-specific T cell program to other indications with unmet medical needs,” concluded Dr. Vera.